Cargando…
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
Immunotherapy represents the new era of cancer treatment because of its promising results in various cancer types. In urological tumors, the use of the immune-checkpoint inhibitors (ICIs) is increasingly spreading. Although not all patients and not all diseases respond equally well to immunotherapy,...
Autores principales: | Schepisi, Giuseppe, Brighi, Nicole, Cursano, Maria Concetta, Gurioli, Giorgia, Ravaglia, Giorgia, Altavilla, Amelia, Burgio, Salvatore Luca, Testoni, Sara, Menna, Cecilia, Farolfi, Alberto, Casadei, Chiara, Tonini, Giuseppe, Santini, Daniele, De Giorgi, Ugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770345/ https://www.ncbi.nlm.nih.gov/pubmed/31641355 http://dx.doi.org/10.1155/2019/7317964 |
Ejemplares similares
-
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020) -
Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019) -
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021) -
CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019) -
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)